Craig L. Slingluff, MD, explains the rationale behind part B1 of the MAVIS study , which is investigating the use of the Seviprotimut-L vaccine in melanoma.
Craig L. Slingluff, MD
Articles by Craig L. Slingluff, MD
Craig L. Slingluff, MD, explains the rationale behind part B1 of the MAVIS study , which is investigating the use of the Seviprotimut-L vaccine in melanoma.
